Baxter International Inc. has reported its second-quarter 2025 results, with sales from continuing operations totaling approximately $2.81 billion, representing a 4% increase on a reported basis and a 1% increase on an operational basis. U.S. sales from continuing operations in the second quarter were approximately $1.54 billion, marking a 3% increase on a reported basis but a 1% decline on an operational basis. International sales from continuing operations in the second quarter were approximately $1.27 billion, reflecting a 6% increase on a reported basis and a 3% increase on an operational basis.
The company's second-quarter U.S. GAAP diluted earnings per share (EPS) from continuing operations stood at $0.24, while adjusted diluted EPS from continuing operations was $0.59, in line with previously issued guidance. On an adjusted basis, net income from continuing operations in the second quarter was $0.59 per diluted share, representing a 28% increase over the prior year.
In terms of segment results, medical products & therapies sales for the second quarter remained flat on a reported basis and increased 1% on an operational basis, totaling approximately $1.32 billion. Healthcare systems & technologies sales for the second quarter amounted to approximately $767 million, representing a 3% increase on a reported basis and a 2% increase on an operational basis. Pharmaceuticals sales for the second quarter totaled approximately $612 million, reflecting a 2% increase on a reported basis and a 1% increase on an operational basis.
Looking ahead, for the full-year 2025, Baxter now expects sales growth from continuing operations of 6% to 7% on a reported basis and 3% to 4% on an operational basis. The company also anticipates adjusted earnings from continuing operations, before special items, of $2.42 to $2.52 per diluted share.
The market has reacted to these announcements by moving the company's shares -2.74% to a price of $28.05. For more information, read the company's full 8-K submission here.
